To determine the effect of statins on the progression of subclinical atherosclerosis in a population of HIV-infected adults on antiretroviral therapy.
Introduction
Inflammation is a fundamental driver of atherosclerosis, and patients with inflammatory autoimmune disease are at high risk of atherothombotic cardiovascular events [1] . Similarly, HIV infection is characterized by chronic inflammation and immune activation [2] and a 1.5-2fold higher risk of myocardial infarction that persists despite effective antiretroviral therapy (ART) [3] . In this population, numerous observational studies have associated circulating biomarkers of inflammation and immune activation with arterial inflammation [4] , subclinical carotid disease [5, 6] , high-risk coronary plaque [7, 8] , and cardiovascular events [9] . It remains unclear, however, whether anti-inflammatory therapies might slow progression of atherosclerosis and reduce events in HIV infection.
Statins are HMG-CoA reductase inhibitors that lower LDL concentrations and dramatically reduce the risk of cardiovascular events in the general population [10] . This reduction in events may be because of an antiinflammatory effect that is independent of LDL lowering [11] . Yet, for patients with higher levels of systemic inflammation, such as systemic lupus erythematosis (SLE) or rheumatoid arthritis, there is mixed evidence that statins reduce progression of subclinical vascular disease or cardiovascular events [12] [13] [14] [15] [16] [17] [18] .
The Stopping Atherosclerosis and Treating Unhealthy Bone with RosuvastatiN in HIV infection (SATURN-HIV) study was designed to test whether statin therapy would reduce progression of atherosclerosis in an HIVinfected population on ARTwith evidence of heightened inflammation or immune activation and low LDL. In prespecified interim analyses, we have previously shown that rosuvastatin reduces soluble markers of inflammation and cellular markers of monocyte and lymphocyte activation [19] [20] [21] . In this study, we report the results of the primary outcome of carotid intima-media thickness (IMT) progression and the secondary outcome of coronary artery calcium (CAC) score progression over 96 weeks.
Methods
The SATURN-HIV study was a double-blind, randomized controlled trial of 10 mg daily rosuvastatin vs. matching placebo with a primary outcome of common carotid artery IMT progression from 0 to 96 weeks. Secondary outcomes included 96-week changes in lipids and CAC score, as well as inflammation and metabolic outcomes. All participants were at least 18 years of age without known coronary disease or uncontrolled diabetes, and on stable ART for at least 3 months with HIV-1 RNA less than 1000 copies/ml. Similarly to the JUPITER (Justification for the Use of Statins in Prevention -an Intervention Trial Evaluating Rosuvastatin) study in HIV-uninfected adults [10] , we included participants with LDL-cholesterol 130 mg/dl or less ( 3.36 mmol/l) and evidence of increased inflammation and/or T-cell activation [high sensitivity C-reactive protein !2 mg/l (!19 mmol/l) and/or CD8 þ CD38 þ HLA-DR þ T cells !19%]. Nineteen percent CD8 þ CD38 þ HLA-DR þ is the median level of patients successfully treated with ART and the 75th percentile for HIV-uninfected controls at our site. Additional inclusion and exclusion criteria are listed in Supplemental Table 1 , http://links.lww.com/QAD/ A939 (Table, Supplemental Digital Content 1, http:// links.lww.com/QAD/A939). Randomization was stratified by use of protease inhibitors and by presence or absence of CAC at study screening. All participants provided written informed consent, and the study was approved by the Institutional Review Board of University Hospitals Case Medical Center (Cleveland, Ohio, USA). The study was registered on the clinicaltrials.gov website (NCT01218802).
Self-reported demographics and medical history were obtained along with a targeted physical exam including height, weight, waist, and hip measurements. Blood was drawn after at least a 12-h fast for glucose, insulin, and lipoproteins. Homeostatic model assessment of insulin resistance (HOMA-IR) was calculated from the fasting glucose and insulin measurements [22] . Ten-year Framingham Risk Score was calculated using a published risk calculator [23] . HIV-1 RNA level and CD4 þ cell count were obtained as part of routine clinical care. Study participants and their physicians were blinded to laboratory values measured for this study; however, they were not blinded from laboratory values checked for clinical purposes during the study period.
Carotid ultrasound
At baseline, 48, and 96 weeks, all participants underwent high resolution ultrasound scanning of the carotid arteries on a Philips iU22 with L9-3 MHz linear array transducer (Philips Healthcare; Andover, Massachusetts, USA) using the consensus protocol of the American Society of Echocardiography [24] . The distal one centimeter of the common carotid artery (CCA) was imaged at three angles (anterior, lateral, and posterior) bilaterally. Far-wall CCA-IMT was measured offline by a single reader (C.T.L.; blinded to treatment assignment and participant characteristics) using semi-automated edge-detection software (Medical Imaging Applications; Coralville, Iowa, USA). The mean-mean CCA-IMT (mean of six segments) was used for all analyses because of its superior reproducibility compared with other segments. Cine clips of the bilateral CCA, internal carotid arteries, and external carotid arteries were used to identify the presence of any plaque, defined as IMT more than 1.5 mm or more than50% thicker than the adjacent vessel. Using this protocol, reproducibility for mean-mean CCA-IMT measurements at our site is high, with intraclass correlation coefficients ranging from 0.961 to 0.968.
Cardiac computed tomography
At baseline, 48, and 96 weeks, all participants also had a noncontrast computed tomography (CT) scan of the chest for CAC scoring. All scans were performed on a 64-slice multidetector CT scanner (Somatom Sensation 64; Siemens Medical Solutions USA, Malvern, Pennsylvania, USA) with 30 Â 0.6 mm collimation, 330 ms rotation time, and 120 kV tube voltage. Three millimeter slices were obtained from the carina to the diaphragm with prospective ECG gating at 60% of the R-R interval. Calcified coronary lesions were defined as areas of at least 6 pixels with density more than 130 Hounsfield units (HU). A single reader (R.G.; blinded to treatment assignment and participant characteristics) quantified total coronary calcium score using the Agatston method.
Biomarkers of inflammation and immune activation
Several biomarkers of systemic inflammation, monocyte activation, endothelial activation, and coagulation were measured in plasma at the baseline visit. IL-6, soluble tumor necrosis factor-a receptors I and II (sTNFR-I and II), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule-1 (sICAM-1), and two soluble markers of monocyte activation (sCD14 and sCD163) were determined by ELISA (R&D Systems; Minneapolis, Minnesota, USA). Plasma cystatin C, high sensitivity C-reactive protein (hsCRP), and fibrinogen were measured by particle-enhanced immunonephelometric assay on a BNII nephelometer (Siemens; Munich, Germany). D-dimer was determined by immunoturbidometric assay on a STA-R Coagulation Analyzer (DiagnosticaStago, Parsippany, New Jersey, USA).
Monocytes and T cells were phenotyped by flow cytometry as previously described [20] . Three monocyte subsets:
CD14 þ CD16 þ , CD14 dim CD16 þ , and CD14 þ CD16 À were each quantified as a percentage of the overall monocyte population. T-cell activation was quantified as the percentage of CD4 þ or CD8 þ cell counts that expressed both CD38 and HLA-DR. Screening CD8 þ cell count activation was measured from fresh whole blood, and entry CD8 þ cell count activation was measured from frozen PBMCs.
Statistical analysis
Baseline characteristics of demographic variables, HIV parameters, cardiovascular risk factors, and subclinical vascular disease were described using median [interquartile range (IQR)] for continuous variables or percentage for categorical variables. Differences between groups, rosuvastatin vs. placebo, were tested with t tests, Mann-Whitney tests, or Fisher's exact tests as appropriate.
The primary outcome variable in this analysis was the change in mean-mean CCA IMT (mm) over the study period (96 weeks). The study was powered to detect a mean difference in 0-96-week IMT change of 0.118 mm with 84% power assuming a sample size of 140 subjects, SD of 0.208 mm, and 20% loss to follow-up.
To measure the effects of statin treatment, we analyzed the IMT change (baseline IMT value subtracted) outcome variable using flexible linear mixed-effects (LME) models with random intercept and random slope. The random-effects in the model account for variations between individuals in the study and correlations within individual repeated CCA-IMT measurements. For variances of the random-effects, which measure the variability of the longitudinal trajectories between individuals that are unexplained by covariates, we used an unstructured variance-covariance matrix. We estimated unadjusted and adjusted treatment effects using the maximum likelihood method. All candidate covariates (from Table 1 ) that were significant at 10% or less level were used to create the final multivariable adjusted model. Although BMI was statistically significantly associated with IMT change at 10% or less level, it was not included in the final model due to multicollinearity with metabolic syndrome. To further explore the effect of statin treatment on CCA-IMT progression among subgroups of patients with the highest levels of inflammation and immune activation, we compared the statin treatment effect for patients with the highest quartile of each individual biomarker (Q4) to all others (Q1-Q3). We then tested for statistical significance of these interactions using linear mixed-effects model as described above.
In this study, a number of subjects withdrew or were lost to follow-up; however, none were due to drug-related adverse events. Detailed dispositions of study subjects are presented in Supplemental Fig. 1 , http://links.lww.com/ QAD/A939 and the Results section. We compared the baseline characteristics of subjects with incomplete data to those who completed the study to check for any systematic biases (Supplementary Table 2 , http:// links.lww.com/QAD/A939). Moreover, to test whether differences between subjects with and without missing data affected our results, we created a binary missing data indicator variable. When this missing data indicator variable was used as a covariate in the LME model, we found that the outcomes did not differ significantly at a less than 5% level. We therefore assumed a missing at random (MAR) mechanism of missingness. The LME model is well suited to produce unbiased parameter estimates with valid statistical inference when missingness is MAR.
All analyses were conducted using STATA 13.0 (StataCorp; College Station, Texas, USA). Of the 202 participants screened, 147 participants met entry criteria and were enrolled (72 into the rosuvastatin arm and 75 into the placebo arm). Twenty-eight participants (9 rosuvastatin; 19 placebo) withdrew or were lost to follow-up prior to the 96-week visit, none due to drugrelated adverse events. One participant had missing 96-week carotid data due to poor image quality. Thus, 123 (84% of participants) had complete 48-week data, and 118 (80%) had complete 96-week data. Three participants (two on rosuvastatin) had premature study drug discontinuation but continued study follow-up. One participant in the rosuvastatin arm discontinued study drug at week 5 due to mayalgias and high creatinine kinase. The other participant in the rosuvastatin arm discontinued at week 37 due to a possible exacerbation of neuropathy symptoms.
Results
The baseline characteristics of all 147 participants at entry are displayed in Table 1 , and characteristics of the 118 subjects with complete 96-week data are shown in Supplemental Table 2 , http://links.lww.com/QAD/ A939 (Table, Supplemental Digital Content 3, http:// links.lww.com/QAD/A939). Overall, the median age was 46 years; 78% were man, and 68% were African American. HIV disease was well controlled; although a quarter of participants had low-level detectable HIV-1 viremia (>50 but <1000 copies/ml) despite ART. Lipid profiles and 10-year Framingham scores were low risk, but nearly one-quarter of participants had metabolic syndrome and at least the one-third had carotid plaque by ultrasound or detectable CAC. Overall, median (IQR) entry CD8 þ cell count activation was lower than screening, likely due to differences in assays being run on frozen vs. fresh samples [28 (22-40) % vs. 12 (9-18)%, screening vs. entry, P < 0.001].
Lipid changes
Participants assigned to the rosuvastatin arm achieved a mean [95% confidence interval (CI)] reduction in LDL concentration of À24 (À29 to À18) mg/dl [À0.62 (À0.75 to À0.47) mmol/l] by week 24 (Figure, Supplemental Digital Content 4, http://links.lww.com/QAD/A939). This approximate 20-25% reduction from baseline was sustained throughout the course of the 96-week study and was statistically different from the placebo arm at all time points. There was a corresponding 0-96-week reduction in non-HDL concentration [À21 (À28 to À13) vs. À3.7 (À12 to 4.4) mg/dl; À0.54 (À0.72 to À0.37) vs. À0.10 (À0.31 to 0.11) mmol/l; statin vs. placebo, P ¼ 0.003] without significant change in HDL [1.1 (À1.3 to 3.5) vs. 1.7 (À2.6 to 6.1) mg/dl; 0.03 (À0.03 to 0.09) vs. 0.04 (À0.07 to 0.16) mmol/l; statin vs. placebo, P ¼ 0.48].
Carotid intima-media thickness
In a linear mixed-effects model, assignment to rosuvastatin 10 mg daily was associated with an unadjusted 0.021 mm (95% CI: 0.003-0.038 mm) lower IMT change over the 96-week study period compared with placebo. This remained statistically significant after adjustment for age, sex, insulin resistance (HOMA-IR), metabolic syndrome, and protease inhibitor use [0.019 mm (95% CI 0.002-0.037 mm), P ¼ 0.03; Table 2 ]. The trajectory of CCA-IMT change over the study period is shown in Fig. 1 . Within the placebo group, CCA-IMT progressed significantly over the course of the 96-week study but was unchanged in the statin group. The difference in IMT change between statin and placebo groups was statistically significant at 48 weeks (P ¼ 0.025) and borderline significant at 96 weeks (P ¼ 0.061) despite a mean (95% CI) annualized rate of CCA-IMT progression in the placebo group that was 2198 AIDS 2016, Vol 30 No 14 In an exploratory subgroup analysis, we examined whether subjects with higher baseline inflammation and immune activation would experience greater reductions in IMT progression with statin therapy compared with those with lower levels of inflammation. Fig. 2 shows the adjusted statin treatment effect on 96week CCA-IMT change by high vs. low subgroups of baseline biomarkers (Q4 vs. Q1-Q3). In linear mixed models with the same covariates as in the primary analysis, there was a borderline statistically significant interaction for sVCAM only (P for interaction ¼ 0.065; all other P > 0.15).
Coronary artery calcium
The percentage of participants with detectable coronary calcium at week 0 and week 96 by treatment group is shown in Fig. 3a 
Discussion
This is the first randomized, placebo-controlled trial to assess the effect of statin therapy on the progression of subclinical carotid artery disease in an HIV-infected cohort on ART with baseline LDL less than 130 mg/dl ( 3.36 mmol/l). In our study, rosuvastatin 10 mg lowered LDL by approximately 20-25% and slowed progression of CCA-IMT during 2 years of follow-up. These findings have important implications for the design of future clinical outcomes studies of statin therapy in patients with chronic inflammatory disorders.
In the general population, the JUPITER study showed that rosuvastatin significantly reduces cardiovascular events among patients with low LDL if they were also selected for modest elevations in hsCRP [10] . Yet, only 62% of HIV-infected patients who experience cardiovascular events would be recommended for statin therapy using the latest 2013 American College of Cardiology/ American Heart Association (ACC/AHA) guidelines [25, 26] . Furthermore, only 26% of patients with highrisk plaque features on CT coronary angiography would meet criteria for therapy [27] . These studies highlight the need to identify biomarkers that not only risk-stratify this population but also identify the patients who are most likely to benefit from statins. We therefore designed our trial to target patients with lower LDL cholesterol, but with elevated markers of inflammation [hsCRP ! 2 mg/l (!19 mmol/l)] and/or CD8 þ T-cell activation (CD8 þ CD38 þ HLA-DR þ T-cells !19%). In the end, only 13 (6%) of 202 subjects screened were excluded on the basis of these criteria, highlighting the high degree of inflammation and immune activation in this treated HIVinfected population. Carotid IMT is a surrogate marker of atherosclerotic vascular risk that has been used in clinical practice and in trials of statin therapy to identify patient subgroups that merit more aggressive treatment for primary prevention [24, 28] ; however, two IMT trials in patients with SLE did not show any statin benefit on IMT progression [12, 17] . Subsequent secondary analyses of APPLE suggested a statin benefit in patients with higher hsCRP [13] and in subjects without vitamin D deficiency [29] .
We hypothesized that similarly to the APPLE study, patients with the highest levels of inflammation would have a greater statin benefit. Although there was a tendency toward greater benefit across many of the biomarkers studied; in adjusted models, we only observed a borderline statistically significant interaction for sVCAM. Interestingly, neither CD8 þ T-cell activation nor hsCRP -the biomarkers chosen for inclusion criteria -seemed to modify the statin effect or associate with the magnitude of CCA-IMT change. We do not believe that this can be explained by the exclusion of subjects with low levels of hsCRP, because over half of the participants had an hsCRP less than 2.0 [20] . Although these subgroup analyses were prespecified, the results should be interpreted with caution and should be viewed only as hypothesis generating. Future studies, including secondary analyses of this trial and others, should consider other potential modifiers of the statin effect to identify which patients are most likely to benefit.
Studies conflict about whether statins alter progression of CAC [30, 31] . Statins may modify the pattern of CAC (e.g., less spotty calcification) and/or components of the Agatston score (e.g. increasing density > volume) [32] in a way that promotes plaque stabilization [33] ; however, the mechanisms by which this occurs remain unclear [34] . In our study, it is therefore not surprising that we saw no difference in incident new CAC or CAC progression between groups.
For patients with chronic treated HIV infection, statins appear to be well tolerated and effective, as long as important drug-drug interactions with ART are considered [35] ; however, there is an urgent need to determine whether statins will reduce clinical cardiovascular end points. In this study of subjects without diabetes, we have previously demonstrated worsening of insulin resistance as early as 48 weeks after initiation of rosuvastatin [37] . Large and longer term clinical trials are needed to assess whether an increased risk of diabetes will jeopardize the favorable effect of statins on cardiovascular risk in the HIV-infected population.
Major strengths of our study are the randomized, placebo-controlled design, and extensive immunophenotyping of participants. Although it is the largest placebo-controlled statin trial conducted in HIV-infected persons to date, it may have been underpowered to detect clinically significant treatment modification by inflammation or immune activation status. These subgroup analyses were also not adjusted for multiple comparisons and should only be considered hypothesis generating.
Our study was also limited by 20% attrition over the 96week study, which reduced study power. We anticipated this rate of dropout in our study population and were powered (at least 80% power) in the planning stage of this study to detect clinically significant changes in the primary CCA-IMT outcome. Although there was differentially more attrition in the placebo group, baseline characteristics of those with complete data remained similar between treatment groups. Lastly, our study included mostly men and African-Americans and may therefore be less generalizeable to women and other racial/ethnic groups.
In conclusion, 10 mg of daily rosuvastatin lowers LDL by 20-25% and appears to slow progression of carotid IMT in patients with treated HIV infection. Although we did not find definitive evidence of treatment effect modification by inflammation status, this should be examined in larger trials with clinical cardiovascular end points in patients with HIV infection or other chronic inflammatory diseases. HL123341 to CTL). Technical support was provided by the Center for AIDS Research, Case Western Reserve University (P30 AI36219). Study drugs and matching placebo were donated by Astra Zeneca. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
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